Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
Sponsor: Revolution Medicines, Inc.
Summary
The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard of care (SOC) observation only.
Official title: RASolute 304: A Phase 3 Multicenter, Open-label, Randomized, 2-Arm Study of Adjuvant Daraxonrasib Versus Standard of Care Observation Following Completion of Neoadjuvant and/or Adjuvant Chemotherapy in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
500
Start Date
2025-12-15
Completion Date
2030-07-10
Last Updated
2026-07-07
Healthy Volunteers
No
Conditions
Interventions
daraxonrasib
oral tablets
Locations (43)
Cedars-Sinai Cancer at Cedars-Sinai Medical Center
Los Angeles, California, United States
University of California, Los Angeles
Los Angeles, California, United States
Stanford Cancer Institute
Palo Alto, California, United States
University of California, San Francisco
San Francisco, California, United States
Rocky Mountain Cancer Centers, LLP
Lakewood, Colorado, United States
Hartford Healthcare
Hartford, Connecticut, United States
Mayo Clinic
Jacksonville, Florida, United States
University of Miami Hospital and Clinics, Sylvester Comprehensive Cancer Center
Miami, Florida, United States
Winship Cancer Institute, Emory University
Atlanta, Georgia, United States
Community Health Network
Indianapolis, Indiana, United States
University of Kansas Medical Center Research Institute, Inc.
Lawrence, Kansas, United States
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins & Sibley Memorial Hospital
Baltimore, Maryland, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Dana Farber Cancer Institute (DFCI)
Boston, Massachusetts, United States
Mayo Clinic Cancer Center
Rochester, Minnesota, United States
Saint Luke's Cancer Institute
Kansas City, Missouri, United States
University of Nebraska Medical Center
Omaha, Nebraska, United States
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada, United States
Laura and Issac Perlmutter Cancer Center at NYU Langone-Ambulatory Care Center
New York, New York, United States
Columbia University Medical Center
New York, New York, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Duke Cancer Center
Durham, North Carolina, United States
Taylor Cancer Research Center
Maumee, Ohio, United States
Avera Cancer Institute
Sioux Falls, South Dakota, United States
SCRI Oncology Partners
Nashville, Tennessee, United States
Texas Oncology - DFW
Dallas, Texas, United States
Texas Oncology - Northeast Texas
Longview, Texas, United States
University of Utah, Huntsman Cancer Institute
Salt Lake City, Utah, United States
Virginia Cancer Specialists
Fairfax, Virginia, United States
CRLCC Eugene Marquis
Rennes, Cedex, France
Hôpital Paul Brousse
Villejuif, Val-De- Marne, France
IEO - Instituto Europeo di Oncologia
Milan, Italy
Kanagawa Cancer Center
Yokohama, Kanagawa, Japan
Cancer Institute Hospital of JFCR
Tokyo, Japan
Pan American Oncology Trials, LLC
San Juan, Puerto Rico
Hospital Clinic de Barcelona
Barcelona, Spain
Hospital Universitario 12 de Octubre
Madrid, Spain
Hospital Universitario Virgen del Rocio
Seville, Spain
University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Medical Centre
Birmingham, United Kingdom
Beatson West of Scotland Cancer Centre
Glasgow, United Kingdom
The Royal Marsden NHS Foundation Trust, Royal Marsden Hospital-London
London, United Kingdom
Imperial College Healthcare NHS Foundation Trust, Hammersmith Hospital
London, United Kingdom
The Christie NHS Foundation Trust
Manchester, United Kingdom